Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies [Phase 4]
Phase 4 trial evaluating olutasidenib for drug-drug interaction in IDH1-mutant malignancies. The study is currently recruiting in AML, gliom…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies [Phase 2]
Phase 2 pilot study to assess feasibility of using decitabine with filgrastim as post-transplant prophylaxis in children and young adults wi…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
A Phase 2 trial update describes a new double epigenetic regimen being studied in relapsed or refractory acute myeloid leukemia, with the st…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: VAC Regimen for AML Patients Who Failed to Response to VA Regimen [Phase 2]
Clinical trial update for a Phase 2 VAC regimen in AML patients who did not respond to VA regimen; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Ziftomenib Maintenance Post Allo-HCT [Phase 1]
A Phase 1 trial evaluating Ziftomenib as maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia (…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients [Phase 2]
Phase 2 trial evaluating maintenance therapy with a hypomethylating agent in favorable-risk acute myeloid leukemia patients is currently rec…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]
A phase 1/2 dose-escalation/expansion study of CA-4948 as monotherapy in acute myeloid leukemia and myelodysplastic syndrome is currently su…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
HEM-SURVIVE is a structured follow-up study for childhood survivors of hematologic malignancies; the trial is currently NOT_YET_RECRUITING a…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
A clinical trial update evaluating the AlloHeme test for assessing chimerism and detecting relapse after bone marrow/hematopoietic cell tran…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating NMS-03592088 in relapsed or refractory acute myeloid leukemia and chronic myelomonocytic leukemia has …
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML [Phase 1]
Phase 1 study of SL-172154 in acute myeloid leukemia and myelodysplastic syndromes was terminated. Results have been posted on 2026-03-18.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation [Phase 1, Phase 2]
A phase 1/2 trial evaluating Revumenib in relapsed/refractory leukemias including MLL/KMT2A rearrangements or NPM1 mutations; currently recr…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) [Phase 3]
This entry describes a Phase 3 clinical trial (VENP-A-QUI) evaluating azacitidine and venetoclax with or without quizartinib as first-line t…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: CIML NK Cells With Venetoclax for AML [Phase 1]
Phase 1 clinical trial of CIML NK Cells with Venetoclax for Acute Myeloid Leukemia is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome [Phase 1]
A Phase 1 trial evaluating total marrow and lymphoid irradiation with fludarabine and melphalan before donor stem cell transplant for high-r…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS [Phase 1]
Phase 1 clinical trial evaluating a combination of epigenetic therapy and sensitising therapy in acute myeloid leukemia, myelodysplastic syn…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide [Phase 2]
Phase 2 trial evaluating HLA-mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide is act…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial [Phase 3]
A Phase 3 randomized trial assessing whether adding venetoclax to the fludarabine/melphalan conditioning regimen improves outcomes for adult…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation [Phase 2]
This Phase 2 clinical trial protocol investigates a post-transplant cyclophosphamide–based graft-versus-host disease prophylaxis approach in…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML [Phase 1]
Phase 1 trial update for voruciclib alone or with venetoclax in various B-cell malignancies and acute myeloid leukemia; the study has been t…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) [Phase 1]
Phase 1 study assessing the safety and preliminary efficacy of venetoclax with escalating doses of omacetaxine in patients with acute myeloi…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms [Phase 2]
A Phase 2 clinical trial evaluating decitabine in combination with JAK inhibitors (ruxolitinib, fedratinib, or pacritinib) for accelerated o…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML [Phase 1, Phase 2]
A study of SLS009 (formerly GFH009), a potent CDK9 inhibitor, in hematologic malignancies including high-risk newly diagnosed acute myeloid …
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Natural Killer-cell Therapy for Acute Myeloid Leukemia [Phase 1, Phase 2]
The clinical trial evaluating natural killer cell therapy for adult acute myeloid leukemia (refractory or relapsed) in Phase 1/2 has been te…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: CINC424A2X01B Rollover Protocol [Phase 4]
Phase 4 rollover protocol for CINC424A2X01B is active but not recruiting, spanning Primary Myelofibrosis, Polycythemia Vera, Graft-versus-ho…